ArticleFrontiers in microbiology2025
Potential value and research frontiers of viruses in inflammatory bowel diseases: a bibliometric analysis.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of inflammatory bowel diseases (IBD) and their interaction with viruses have attracted growing scientific attention, as viral infections and gut virome dysregulation are increasingly recognized as key drivers of IBD onset, disease activity, and treatment responses. However, a systematic analysis of research trends in this field is lacking, leaving critical gaps in understanding how viral factors shape IBD pathogenesis and clinical management. This study conducted a bibliometric analysis to map trends, key areas, and emerging topics in the virus-IBD field from 2014 to 2024, with a focus on the pathogenic roles of viruses. The goal was to inform future research directions and bridge the gap between basic science and clinical practice. Methods: Publications related to virus-IBD were retrieved from the Web of Science Core Collection. The analysis employed VOSviewer, CiteSpace, and HistCite software to explore bibliometric dimensions, including annual publication trends, contributions by countries/regions and institutions, collaboration networks, highly cited references, citation bursts, and keyword co-occurrence and evolution. Results: Among 3,225 publications analyzed, three distinct phases were observed: fluctuating growth (2014-2019), a sharp rise (2020-2021), and a gradual decline (2022-2024). The United States (996 publications) and China (507 publications) were the dominant contributors to the field. The Mayo Clinic led in institutional publication output, while Jean-Frederic Colombel and Silvio Danese were among the most prolific and cited authors. Conclusion: This study establishes an integrated knowledge framework of virus-IBD research, highlighting three essential domains: gut virome regulation and therapy, clinical management of opportunistic viral infections, and IBD care in the COVID-19 era. It further clarified the pathophysiological interplay between viral factors and IBD. By synthesizing key contributors, core themes, and evolutionary trends, this work provides a practical foundation for guiding translational research and promoting clinical innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.